Disrupting resistance to EGFR-specific tyrosine kinase inhibitors in TP53-mutated lung carcinoma cell lines by proteasome inhibition

被引：0
|
作者：
Orth, Franziska
Schaefer, Benjamin
Harsch, Annika
Weller, Sandra
Beigl, Tobias
Barber, Lynn
Kopp, Hans-Georg
Essmann, Frank
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2532
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2532
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Resistance in EGFR-specific tyrosine kinase inhibitors in Non-Small Lung Cancer cell lines
    Orth, F.
    Schaefer, B.
    Harsch, A.
    Weller, S.
    Beigl, T.
    Barber, L.
    Kopp, H. -G
    Essmann, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 228 - 228
  • [2] Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo
    Gurtner, Kristin
    Kryzmien, Zofia
    Koi, Lydia
    Wang, Meng
    Benes, Cyril H.
    Hering, Sandra
    Willers, Henning
    Baumann, Michael
    Krause, Mechthild
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (02) : 472 - 477
  • [3] TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC
    Canale, M.
    Ludovini, V.
    Crino, L.
    Dazzi, C.
    Chiadini, E.
    Capelli, L.
    Papi, M.
    Mariotti, M.
    De Luigi, N.
    Minuti, G.
    Calistri, D.
    Baglivo, S.
    Chiari, R.
    Bonafe, M.
    Delmonte, A.
    Ulivi, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S591 - S591
  • [4] Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators
    Marrocco, Ilaria
    Yarden, Yosef
    CANCERS, 2023, 15 (20)
  • [5] Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung? A Case Report
    Aroldi, Francesca
    Bertocchi, Paola
    Meriggi, Fausto
    Abeni, Chiara
    Ogliosi, Chiara
    Rota, Luigina
    Zambelli, Claudia
    Bna, Claudio
    Zaniboni, Alberto
    CASE REPORTS IN ONCOLOGY, 2014, 7 (02): : 478 - 483
  • [6] The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer
    Kono, Scott A.
    Marshall, Marianne E.
    Ware, Kathryn E.
    Heasley, Lynn E.
    DRUG RESISTANCE UPDATES, 2009, 12 (4-5) : 95 - 102
  • [7] Role of TP53 Mutations in Determining Primary Resistance to First-Line Tyrosine Kinase Inhibitors in EGFR-Mutated NSCLC Patients
    Ulivi, Paola
    Canale, Matteo
    Delmonte, Angelo
    Petracci, Elisabetta
    Chiadini, Elisa
    Dazzi, Claudio
    Papi, Maximilian
    Capelli, Laura
    Casanova, Claudia
    De Luigi, Nicoletta
    Mariotti, Marita
    Gamboni, Alessandro
    Chiari, Rita
    Bennati, Chiara
    Calistri, Daniele
    Ludovini, Vienna
    Crino, Lucio
    Amadori, Dino
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1188 - S1189
  • [8] Tumor heterogeneity via AXL activation on primary resistance to EGFR tyrosine kinase inhibitors in EGFR mutated lung cancer
    Yamada, Tadaaki
    Nakamura, Ryota
    Fujii, Hiroyuki
    Yaoi, Takeshi
    Itoh, Kyoko
    Tokuda, Shinsaku
    Takayama, Koichi
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Cytomorphologic and Molecular Evolution of EGFR-Mutated Lung Adenocarcinomas with Acquired Resistance to Tyrosine Kinase Inhibitors
    Doxtader, Erika E.
    Brainard, Jennifer A.
    Sturgis, Charles D.
    Velcheti, Vamsidar
    Zhang, Yaxia
    MODERN PATHOLOGY, 2017, 30 : 93A - 93A
  • [10] Cytomorphologic and Molecular Evolution of EGFR-Mutated Lung Adenocarcinomas with Acquired Resistance to Tyrosine Kinase Inhibitors
    Doxtader, Erika E.
    Brainard, Jennifer A.
    Sturgis, Charles D.
    Velcheti, Vamsidar
    Zhang, Yaxia
    LABORATORY INVESTIGATION, 2017, 97 : 93A - 93A
12345